Immuron Completes Capital Consolidation

Melbourne, Australia – Thursday, 20th November 2014: Australian biopharmaceutical company Immuron Limited (ASX: IMC) wishes to advise that the process to consolidate the securities of the Company on a 40:1 basis, as approved by Shareholders at the company's Annual General Meeting convened on 13 November 2014, has now been completed in accordance with section 254H(1) of the Corporations Act.

As explained by the Company in its letter dated 14 October 2014, the consolidation does not affect the value of the shareholdings, which remains the same. The price of each share has increased by a multiple of 40 and the number of shares owned correspondingly decreased by a multiple of 40.

The consolidation of the Company's securities comprised of the following:

Fully Paid Ordinary Shares:

	Pre-Consolidation			Post-Consolidation		
ASX Code	**Qty on Issue**	**Share Price**	**Market Cap**	**Qty on Issue**	**Share Price**	**Market Cap**
IMC	2,995,662,120	$0.006	$17.97M*	74,891,316	$0.24	$17.97M*

** Note: The Company's Total Market Capitalisation remains unchanged.*

Listed Options:

ASX Code	Expiry Date of Options	Pre-Consolidation		Post-Consolidation	
		Qty on Issue	Exercise Price	Qty on Issue	Exercise Price
IMCOA	30 April 2015	115,995,306	$0.0389	2,899,197	$1.556

Should you have any queries in relation to your security holding, please contact the Company's share registry Security Transfer Registrars on +61 (0)8 9315 2333 or registrar@securitytransfer.com.au.

Contacts:

Amos Meltzer
Chief Executive Officer
+61 (0)437 587 680

Investor Relations
Amanda Loh, Buchan Consulting
+61 (0)3 9866 4722

Websites: www.immuron.com and www.travelan.com

About Immuron

Immuron (ASX:IMC) is a Melbourne based biopharmaceutical company focused on the development of oral immunotherapy treatments using dairy-derived antibody products. Immuron has a unique technology platform producing products all with a very high safety profile. Immuron sells Travelan®, the world's first effective over-the-counter preventative for travellers' diarrhoea, currently available in Australia and Canada. Two Phase II trials of IMM-124E for the treatment of inflamed fatty liver diseases are about to commence. In addition, Immuron is progressing preclinical trials for IMM-529 for the treatment of *Clostridium difficile* infection due to the overuse of antibiotics. Immuron's main scientific alliances are with Hadassah Medical Center (Israel) and Monash University (Australia).